{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:12:38Z","timestamp":1784657558032,"version":"3.55.0"},"reference-count":63,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Nosocomial pneumonia (NP) represents a leading nosocomial infection and results in substantial morbidity and cost. Over the last several years, the evidence has evolved which directs our approach to NP. Specifically, the definition of NP and classification of its various subtypes has expanded to capture nuances among various phenotypes of this syndrome. For example, segregating those with hospital-acquired pneumonia (HAP) based on whether they subsequently require mechanical ventilation has been shown to be important. Likewise, newer data indicate the true economic cost of NP and underscore the diverse range of pathogens that can cause NP. Moreover, multidrug-resistant (MDR) bacteria have become a major threat in NP. Fortunately, newer simple preventive strategies have been tested and found to be effective at reducing the incidence of NP. Should prevention fail, a range of new antibiotics have been formally studied in NP and found to be effective. Some of these novel agents have relatively broad ranges of activity and are in vitro active against select MDR organisms. Others, however, are narrower in spectrum and directed against specific problem bacteria. In short, the literature in the field of NP has progressed rapidly, and clinicians require a clear appreciation of these changes so as to improve patient outcomes.<\/jats:p>","DOI":"10.3390\/pathogens13060495","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T10:08:43Z","timestamp":1718014123000},"page":"495","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improving Outcomes in Nosocomial Pneumonia: Recent Evidence and More Challenges"],"prefix":"10.3390","volume":"13","author":[{"given":"Ihab H.","family":"Masri","sequence":"first","affiliation":[{"name":"Pulmonary and Critical Care Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Busack","sequence":"additional","affiliation":[{"name":"Critical Care Medicine, University of Michigan-West, Wyoming, MI 49519, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-8328","authenticated-orcid":false,"given":"Andrew F.","family":"Shorr","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Sabo, S.R., Venkatramanan, A., and Shorr, A.F. (2024). At the Intersection of Critical Care and Infectious Diseases: The Year in Review. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030562"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.idc.2023.12.004","article-title":"Management of Ventilator-Associated Pneumonia: Guidelines","volume":"38","author":"Metersky","year":"2024","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/cid\/ciad447","article-title":"Improving Sepsis Outcomes in the Era of Pay-for-Performance and Electronic Quality Measures: A Joint IDSA\/ACEP\/PIDS\/SHEA\/SHM\/SIDP Position Paper","volume":"78","author":"Rhee","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s13054-014-0596-8","article-title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: A retrospective cohort study","volume":"18","author":"Zilberberg","year":"2014","journal-title":"Crit. Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1097\/CCM.0000000000000516","article-title":"Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock","volume":"42","author":"Scolari","year":"2014","journal-title":"Crit. Care Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2314185","DOI":"10.1001\/jamanetworkopen.2023.14185","article-title":"Incidence and Outcomes of Non-Ventilator-Associated Hospital-Acquired Pneumonia in 284 US Hospitals Using Electronic Surveillance Criteria","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/CCM.0000000000005298","article-title":"Descriptive Epidemiology and Outcomes of Nonventilated Hospital-Acquired, Ventilated Hospital-Acquired, and Ventilator-Associated Bacterial Pneumonia in the United States, 2012\u20132019","volume":"50","author":"Zilberberg","year":"2022","journal-title":"Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e0667","DOI":"10.1097\/CCE.0000000000000667","article-title":"Inappropriate Empiric Therapy Impacts Complications and Hospital Resource Utilization Differentially Among Different Types of Bacterial Nosocomial Pneumonia: A Cohort Study, United States, 2014\u20132019","volume":"4","author":"Zilberberg","year":"2022","journal-title":"Crit. Care Explor."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/cid\/ciy543","article-title":"A systematic review and meta-analysis of ventilator-associated pneumonia in adults in Asia: An analysis of national income level on incidence and etiology","volume":"68","author":"Bonell","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s10096-016-2703-z","article-title":"Nosocomial pneumonia in 27 ICUs in Europe: Perspectives from the EU-VAP\/CAP study","volume":"36","author":"Koulenti","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s12028-019-00773-w","article-title":"Incidence, Risk Factors, and Outcomes of Ventilator-Associated Pneumonia in Traumatic Brain Injury: A Meta-analysis","volume":"32","author":"Li","year":"2020","journal-title":"Neurocritical Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jcrc.2005.08.005","article-title":"Incidence, risk factors, and outcome of ventilator-associated pneumonia","volume":"21","author":"Tejerina","year":"2006","journal-title":"J. Crit. Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajic.2014.11.014","article-title":"National healthcare safety network report, data summary for 2013, device-associated module","volume":"43","author":"Dudeck","year":"2015","journal-title":"Am. J. Infect. Control"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0002-9343(93)90060-3","article-title":"Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay","volume":"94","author":"Fagon","year":"1993","journal-title":"Am. J. Med."},{"key":"ref_15","first-page":"2709","article-title":"Ventilator-associated pneumonia and mortality: A systematic review of observational studies","volume":"37","author":"Melsen","year":"2009","journal-title":"Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1097\/CCM.0b013e3182281f33","article-title":"Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies","volume":"39","author":"Melsen","year":"2011","journal-title":"Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1164\/rccm.201105-0867OC","article-title":"Attributable mortality of ventilator-associated pneumonia: A reappraisal using causal analysis","volume":"184","author":"Bekaert","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/664049","article-title":"Economic impact of ventilator-associated pneumonia in a large matched cohort","volume":"33","author":"Kollef","year":"2012","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1751143717740804","article-title":"Cost of treating ventilator-associated pneumonia post cardiac surgery in the National Health Service: Results from a propensity-matched cohort study","volume":"19","author":"Luckraz","year":"2018","journal-title":"J. Intensive Care Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e61e111","DOI":"10.1093\/cid\/ciw504","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT)","volume":"50","author":"Torres","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00134-020-06036-z","article-title":"Diagnosis of ventilator-associated pneumonia in critically ill adult patients-a systematic review and meta-analysis","volume":"46","author":"Fernando","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1097\/CCM.0000000000003129","article-title":"Diagnostic Accuracy of Chest Radiograph, and When Concomitantly Studied Lung Ultrasound, in Critically Ill Patients With Respiratory Symptoms: A Systematic Review and Meta-Analysis","volume":"46","author":"Winkler","year":"2018","journal-title":"Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1136\/thoraxjnl-2021-216990","article-title":"Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: The INHALE WP1 study","volume":"77","author":"Enne","year":"2022","journal-title":"Thorax"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jinf.2022.09.003","article-title":"Molecular point-of-care testing for lower respiratory tract pathogens improves safe antibiotic de-escalation in patients with pneumonia in the ICU: Results of a randomised controlled trial","volume":"85","author":"Poole","year":"2022","journal-title":"J. Infect."},{"key":"ref_26","first-page":"1","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015\u20132017","volume":"41","author":"Abner","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zilberberg, M.D., Nathanson, B.H., Puzniak, L.A., Dillon, R.J., and Shorr, A.F. (2022). The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012\u20132019. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07755-y"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.chest.2017.12.005","article-title":"The Burden of Viruses in Pneumonia Associated With Acute Respiratory Failure: An Underappreciated Issue","volume":"154","author":"Shorr","year":"2018","journal-title":"Chest"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1017\/ice.2022.223","article-title":"The importance of viruses in ventilator-associated pneumonia","volume":"44","author":"Shorr","year":"2023","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MCC.0000000000000908","article-title":"Ventilator-associated pneumonia among SARS-CoV-2 acute respiratory distress syndrome patients","volume":"28","author":"Fumagalli","year":"2022","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.202106-1354OC","article-title":"Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia","volume":"204","author":"Pickens","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","first-page":"1610","article-title":"Comparative evaluation of ventilator-associated pneumonia in critically ill COVID- 19 and patients infected with other corona viruses: A systematic review and meta-analysis","volume":"92","author":"Jain","year":"2021","journal-title":"Monaldi Arch. Chest Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13613-020-00775-4","article-title":"Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: A retrospective cohort study","volume":"10","author":"Luyt","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s13054-022-04264-x","article-title":"Statistics on steroids: How recognizing competing risks gets us closer to the truth about COVID-19-associated VAP","volume":"26","author":"Shorr","year":"2022","journal-title":"Crit. Care"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Vel\u00e1squez-Garcia, L., Mejia-Sanjuanelo, A., Viasus, D., and Carratal\u00e0, J. (2022). Causative Agents of Ventilator-Associated Pneumonia and Resistance to Antibiotics in COVID-19 Patients: A Systematic Review. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061226"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1017\/ice.2022.88","article-title":"Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 Update","volume":"43","author":"Klompas","year":"2022","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_37","first-page":"CD008367","article-title":"Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia","volume":"12","author":"Zhao","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00134-018-5171-3","article-title":"Effects of chlorhexidine gluconate oral care on hospital mortality: A hospital-wide, observational cohort study","volume":"44","author":"Deschepper","year":"2018","journal-title":"Intensive Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/idh.12560","article-title":"Use of toothbrushing in conjunction with chlorhexidine for preventing ventilator-associated pneumonia: A random-effect meta-analysis of randomized controlled trials","volume":"21","author":"Sozkes","year":"2023","journal-title":"Int. J. Dent. Hyg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamainternmed.2023.6638","article-title":"Association Between Daily Toothbrushing and Hospital-Acquired Pneumonia: A Systematic Review and Meta-Analysis","volume":"184","author":"Ehrenzeller","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1056\/NEJMoa2310307","article-title":"Inhaled amikacin to prevent ventilator-associated pneumonia","volume":"389","author":"Ehrmann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S2213-2600(23)00471-X","article-title":"Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: A multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial","volume":"12","author":"Lasocki","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Breijyeh, Z., Jubeh, B., and Karaman, R. (2020). Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules, 25.","DOI":"10.3390\/molecules25061340"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-Lactamase-Producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-021-01471-8","article-title":"Imipenem\/Cilastatin\/Relebactam: A review in gram-negative bacterial infections","volume":"81","author":"Heo","year":"2021","journal-title":"Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A Randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): A randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: The TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","article-title":"Novel beta-lactamase inhibitors: Unlocking their potential in therapy","volume":"77","author":"Wong","year":"2017","journal-title":"Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"Doi","year":"2017","journal-title":"Virulence"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/cid\/ciad094","article-title":"Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections","volume":"76","author":"Shields","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1093\/cid\/ciad093","article-title":"Sulbactam-durlobactam: A step forward in treating carbapenem-resistant Acinetobacter baumannii (CRAB) infections","volume":"76","author":"Watkins","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jhm.2477","article-title":"Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study","volume":"11","author":"Zilberberg","year":"2016","journal-title":"J. Hosp. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","article-title":"Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis","volume":"24","author":"Liu","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: A multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"9","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): A randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13054-021-03694-3","article-title":"Ceftolozane\/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: Subset analysis of the ASPECT-NP randomized, controlled phase 3 trial","volume":"25","author":"Timsit","year":"2021","journal-title":"Crit. Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2213-2600(23)00418-6","article-title":"Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): A multicentre, individually randomised, open-label, non-inferiority trial","volume":"12","author":"Mo","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jama.2023.10598","article-title":"MERCY Investigators. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial","volume":"330","author":"Monti","year":"2023","journal-title":"JAMA"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/6\/495\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:56:17Z","timestamp":1760108177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/6\/495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":63,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["pathogens13060495"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13060495","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]}}}